Companies · Healthtech
San Francisco · CA, USA · Healthtech · founded 2022 · https://arintra.com
Diligence memoA one-page analyst read on Arintra — recommendation, valuation, rhythm, risks.→Arintra: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Arintra is one of 2138 Healthtech companies tracked from San Francisco, CA, USA, on record since 2022. By capital raised it ranks in the long tail (ahead of 8% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Medical coding automation
US hospitals and clinics are losing $125B every year due to delayed and inaccurate medical coding. Arintra is solving this problem by automating medical coding using clinical AI. Arintra converts a patient chart instantly into insurance claims with 96% accurate medical codes and zero human intervention. Arintra has partnered with several provider clients that includes health systems and large physician groups with 100% success. Through automation of these charts, Arintra has reduced undercoding by 11% and coding-related claim denials by 43%. Arintra is headquartered in Austin, Texas. Arintra is bi-directionally integrated with leading EHRs including Epic, Athena, Cerner, etc. to process patient charts directly from the EHR to create a direct-to-billing claim. This direct-to-billing claim includes precise E/M levels, CPT, ICD-10, HCC, HCPCS codes with appropriate modifiers and units. Both founders have PhDs in AI, significant ML and NLP experience, 60+ patents and publications, and a combined 20+ years of experience working at B2B companies and startups in Silicon Valley.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 8% of sector peers (real $). Modeled value above 8% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Arintra is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| 10x | Healthtech | — | — | — | same sector |
| 1 Health Providence, Inc. | Healthtech | Pre-Seed | $175K | $1.9M | same sector |
| 4C Health Solutions, Inc. | Healthtech | Seed | $1.3M | $1.9M | same sector |
| Aatru Medical LLC | Healthtech | Seed | $5.7M | $335K | same sector |
| Acolyte Health Inc. | Healthtech | Seed | $2.1M | $1.2M | same sector |
| AcQumen Medical, Inc. | Healthtech | Pre-Seed | $341K | $758K | same sector |
| Adentris | Healthtech | — | — | — | same sector |
| Advanta Health Solutions, Inc. | Healthtech | Pre-Seed | $487K | $2.8M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Knowtex Making doctors 2x more efficient with AI note-taking & charge capture | Healthtech | — | — | 77% |
| Codes Health Medical Record Retrieval with Zero Human Error | Legaltech | — | — | 76% |
| Adentris Real-time AI Compliance for Medical Documentation | Healthtech | — | — | 76% |
| Claim Health AI Revenue Platform for Post-Acute Care | Healthtech | — | — | 76% |
| Latent Medical language models to automate healthcare operations | Healthtech | — | — | 75% |
| Aegis AI Agents to win denied health insurance claims. | Insurance | — | — | 75% |
| Lamar Health Take Care of Shitty Paperwork for Expensive Drugs | Healthtech | — | — | 74% |
| Locata AI Referral Automation for Primary Care Clinics | Healthtech | — | — | 74% |
See where Arintra sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Arintra, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.